Kidney disease is a major complication of diabetes that markedly increases risk of cardiovascular disease (CVD) and mortality. Albuminuria, which is believed to reflect hemodynamic disturbances within the glomerulus, has long been identified as a major prognostic indicator in individuals with diabetes ([@B1],[@B2]). Impaired glomerular filtration rate (GFR), a complementary sign of kidney damage, is also associated with increased risk ([@B2],[@B3]). As a result, screening for kidney disease using urinary albumin and serological markers of kidney function has become a cornerstone of diabetes care, facilitating targeted interventions to prevent CVD and kidney disease progression ([@B4]).

Albuminuria and impaired GFR may provide additive prognostic information regarding health outcomes in diabetes. However, the joint association of albuminuria and impaired GFR with mortality has not been defined in this setting, because few studies have evaluated albuminuria and GFR simultaneously, studies that have reached different conclusions ([@B3],[@B5]), and GFR has only been estimated using serum creatinine. GFR estimated from serum cystatin C may reflect kidney function more precisely than GFR estimated using traditional serum creatinine-based methods and is more strongly linked with adverse health outcomes in community-based, mostly nondiabetic populations ([@B6],[@B7]).

We examined associations of cystatin C--estimated GFR, creatinine-estimated GFR, change in estimated GFR over time, and albuminuria with mortality among older adults with diabetes. The relationship of kidney disease with mortality may be particularly important among older adults. In the general population, traditional cardiovascular risk factors predict CVD weakly in older compared with younger adults, and the prognostic value of kidney disease is increased ([@B8]). Our aim was to assess whether cystatin C--estimated GFR would provide additive prognostic information to urine albumin excretion and to compare the strength of the association with mortality with that of creatinine-estimated GFR.

RESEARCH DESIGN AND METHODS
===========================

The Cardiovascular Health Study (CHS) is a prospective, community-based cohort designed to study risk factors for the development and progression of CVD in individuals aged ≥65 years ([@B9]). Participants were recruited from four U.S. communities: Forsyth County, North Carolina; Sacramento County, California; Washington County, Maryland; and Pittsburgh, Pennsylvania. Eligible participants were sampled using Medicare eligibility lists, were not institutionalized, and were expected to remain in the area for at least 3 years. Individuals who were wheelchair-bound in the home or receiving hospice treatment, radiation therapy, or chemotherapy for cancer were excluded. The original CHS cohort of 5,201 participants was enrolled in 1989--1990, with an additional 687 predominantly African American participants enrolled in 1992--1993. Urine albumin was first measured in 1996--1997.

The current study includes CHS participants who in 1996--1997 had diabetes as well as measurements of serum cystatin C, serum creatinine, and urine albumin. At this examination, blood glucose was measured after a 12-h fast and again 2 h after a 75-g oral glucose load. Diabetes was defined as use of insulin or oral hypoglycemic agents, fasting blood glucose ≥126 mg/dl, and/or 2-h postchallenge blood glucose ≥200 mg/dl ([@B4]). Measurements of serum cystatin C, serum creatinine, and urine albumin were available for 691 of 814 participants meeting the criteria for diabetes (85%). (A full list of the principal CHS investigators and institutions can be found at <http://www.chs-nhlbi.org/pi.htm>.)

Measurements of kidney disease
------------------------------

Serum cystatin C was measured using a BNII nephelometer (N Latex Cystatin C; Dade Behring, Deerfield, IL). Coefficients of variation ranged from 2.0 to 2.8% (intra-assay) and from 2.3 to 3.1% (interassay). GFR was estimated from cystatin C (eGFR~CYS~) using 1996--1997 (baseline) measurements and the following equation: eGFR~CYS~ = 76.7 × \[cystatin C\]^−1.18^ ([@B10]). Previous change in eGFR~CYS~ over time was calculated for each participant using additional measurements from 1989 to 1990 and/or 1992 to 1993 and linear regression ([@B11]). Serum creatinine was measured in 1996--1997 (baseline) with the Kodak Ektachem 700 Analyzer (Eastman Kodak, Rochester, NY), which uses a colorimetric method. The mean coefficient of variation was 1.94% (range 1.16--3.60). Serum creatinine was calibrated to Cleveland Clinic values using indirect calibration to National Health and Nutrition Examination Survey (NHANES) III data and then was used to estimate GFR with the four-variable Modification of Diet in Renal Disease (MDRD) formula ([@B12]). Estimated GFR was evaluated as both a continuous and a dichotomous variable (\< or \>60 ml/min per 1.73 m^2^) ([@B13]). Urine was collected as a single morning void. Urine albumin was measured by rate nephelometry using the Array 360 CE Protein Analyzer (Beckman Instruments, Fullerton, CA). Urine creatinine was measured using a Kodak Ektachem 700 Analyzer. Albuminuria was quantified as urine albumin-to-creatinine ratio (ACR), expressed in milligrams per gram and evaluated as both a continuous (log-transformed) and a categorical variable, defined using a threshold of 30 mg/g ([@B4],[@B13]).

Ascertainment of mortality
--------------------------

All-cause mortality was ascertained by examination of death certificates, inpatient records, nursing home or hospice records, physician questionnaires, and autopsy reports ([@B6],[@B7],[@B11]). For this study, participants were followed from their 1996--1997 visit through 30 June 2006. CVD mortality, defined as death from coronary heart disease, myocardial infarction, sudden cardiac death, or stroke, was evaluated as a secondary outcome.

Covariates
----------

Covariates were measured at the 1996--1997 CHS study visit. Race (Caucasian or African American) and smoking status were defined by self-report. Hypoglycemic medication use was classified as none, oral medications only, or insulin (with or without oral medications) ([@B14]). Prevalent CVD was defined as diagnoses of coronary heart disease, stroke, or transient ischemic attack. Hypertension was defined as use of antihypertensive medications, systolic blood pressure ≥140 mmHg, or diastolic blood pressure ≥90 mmHg ([@B15]). Total cholesterol was measured using standard enzymatic methods. C-reactive protein was measured with an enzyme-linked immunosorbent assay developed in the CHS laboratory. Duration of diabetes was defined as \<4 years if the definition of diabetes above was first met at the 1996--1997 CHS study visit ([@B4]). Among participants who entered the CHS in 1989--1990, duration of diabetes was classified as ≥7 years if the definition of diabetes above was met at the 1989--1990 CHS study visit and 4--7 years if it was first met at the 1992--93 CHS visit. Among participants who entered in 1992--1993 and had diabetes at that time, duration was classified as ≥7 years if duration was self-reported as \>3 years, and otherwise classified as 4--7 years.

Statistical analysis
--------------------

We examined the distribution of demographic characteristics, traditional cardiovascular risk factors, prevalent CVD, and laboratory measures by level of eGFR~CYS~ (\< or \>60 ml/min per 1.73 m^2^) ([@B13]). We generated descriptive summary statistics for each category using means ± SD (or median and interquartile range) for continuous variables and proportions for dichotomous variables. Within categories of kidney disease defined by estimated GFR or urine ACR, we examined mortality rates per 100 person-years. Cox proportional hazards models were used to assess associations of kidney disease with all-cause and cardiovascular mortality in unadjusted and adjusted models. Covariates were selected on the basis of their biological plausibility to confound associations of kidney disease and mortality. The fully adjusted model included age, sex, race, diabetes duration, hypoglycemia medications, hypertension, BMI, smoking, cholesterol, lipid-lowering medications, prevalent CVD, and prevalent heart failure. Interaction of estimated GFR with urine ACR was tested on the multiplicative scale using the likelihood ratio test and on the additive scale using the synergy index. Cumulative survival by eGFR~CYS~ and urine ACR was plotted using the Kaplan-Meier method and compared using the log-rank test.

The ability of the models to discriminate between participants with and without all-cause mortality was estimated by computing the c-index, a generalization of the c-statistic or the area under the curve, which allows for censored data. Because prediction models commonly show overly optimistic performance (i.e., overfitting) the c-index was computed with bootstrap sampling using the Design library in S-PLUS. We also estimated the relative contribution to global risk by each individual measure of kidney function using the variable and model likelihood ratio χ^2^ statistic. All analyses were performed using S-Plus (release 8.0; Insightful, Seattle, WA) and SPSS statistical software (release 15.0.1.1; SPSS, Chicago, IL).

RESULTS
=======

Baseline characteristics
------------------------

In 1996--1997 (baseline for this study), mean age was 77 years, 58% of participants were female, and 19% were African American ([Table 1](#T1){ref-type="table"}). Participants with lower GFR estimated from cystatin C (eGFR~CYS~) were slightly older and were more likely to be male, to have CVD, to smoke, and to have hypertension ([Table 1](#T1){ref-type="table"}). eGFR~CYS~ was weakly correlated with urine ACR (Pearson ρ = −0.267). Of the participants, 27% with eGFR~CYS~ ≥ 60 ml/min per 1.73 m^2^ and 47% of those with eGFR~CYS~ \< 60 ml/min per 1.73 m^2^ had urine ACR ≥30 mg/g. eGFR~CYS~ was highly correlated with MDRD-estimated GFR (eGFR~MDRD~, ρ = 0.762). eGFR~MDRD~ was \<60 ml/min per 1.73 m^2^ for 151 participants (22%).

###### 

Baseline characteristics of 691 CHS participants with diabetes by serum cystatin C--estimated GFR

                                                                        Estimated GFR       
  --------------------------------------------------------------------- ------------------- -------------------
  *n*                                                                   467                 224
  Cystatin C--estimated GFR (ml/min per 1.73 m^2^)                      80 ± 16             45 ± 10
  Medical history                                                                           
      Age (years)                                                       77 ± 4              79 ± 5
      Sex (female)                                                      284 (61)            116 (52)
      Race (African American)                                           97 (21)             37 (17)
      Duration of diabetes                                                                  
          \<4 years                                                     189 (41)            88 (39)
          4--7 years                                                    60 (13)             21 (9)
          ≥7 years                                                      218 (47)            115 (51)
      CVD                                                               150 (32)            101 (45)
          Coronary heart disease                                        124 (27)            83 (37)
          Stroke                                                        31 (7)              24 (11)
          Transient ischemic attack                                     20 (4)              15 (7)
      Congestive heart failure                                          43 (9)              49 (22)
      Smoking                                                           232 (50)            122 (56)
      Hypertension                                                      280 (60)            156 (70)
  Medications                                                                               
      Hypoglycemic medications                                                              
          None                                                          235 (50)            118 (53)
          Oral medications only                                         183 (39)            65 (29)
          Insulin                                                       49 (11)             41 (18)
      Antihypertensive medications                                      321 (69)            186 (83)
          ACE inhibitors                                                94 (20)             78 (35)
      Lipid-lowering medications                                        61 (13)             40 (18)
  Physical measurements                                                                     
      BMI (kg/m^2^)                                                     28.2 ± 5.0          28.9 ± 4.9
      Systolic blood pressure (mmHg)                                    137 ± 20            139 ± 20
      Diastolic blood pressure (mmHg)                                   69 ± 12             68 ± 11
  Laboratory measurements                                                                   
      Total cholesterol (mg/dl)                                         201 ± 41            198 ± 43
      C-reactive protein (mg/l)                                         3.31 (1.48--6.64)   4.18 (2.00--7.88)
      MDRD estimated GFR                                                                    
          Mean ± SD (ml/min per 1.73 m^2^)                              91 ± 22             59 ± 17
          \<60 ml/min per 1.73 m^2^                                     27 (6)              124 (55)
      Change in cystatin C--estimated GFR (ml/min per 1.73 m^2^/year)   −1.25 ± 2.27        −2.85 ± 2.71
      Urine ACR (mg/g)                                                                      
          Median (interquartile range) (mg/g)\*                         11 (6--32)          24 (10--111)
          ≥30 mg/g                                                      124 (27)            105 (47)

Data are means ±SD, *n* (%), or median (interquartile range).

Mortality
---------

Over 10 years of follow-up, 378 participants (55%) died. The mortality rate was 7.7 per 100 person-years, and median survival was 8.8 years.

Cystatin C versus creatinine
----------------------------

Lower eGFR~CYS~ and lower eGFR~MDRD~ were each associated with increased risk of mortality ([Table 2](#T2){ref-type="table"}). The association of each GFR estimate with mortality was monotonic and roughly linear (supplementary Fig. 1, available in an online appendix at <http://care.diabetesjournals.org/cgi/content/full/dc09-0191/DC1>). However, the magnitude of association with mortality was modestly greater for eGFR~CYS~ compared with eGFR~MDRD~, whether estimated GFR was evaluated as a categorical or continuous variable ([Table 2](#T2){ref-type="table"}). Results were similar for all-cause and cardiovascular mortality. GFR \<60 ml/min per 1.73 m^2^ estimated from cystatin C was associated with a 73% increased risk of mortality after full adjustment (*P* \< 0.001). When both eGFR~CYS~ and eGFR~MDRD~ were included simultaneously in the fully adjusted model, eGFR~CYS~ but not eGFR~MDRD~ was associated with increased risk of mortality: hazard ratios (HRs) 1.21 (95% CI 1.10--1.33) and 1.00 (0.94--1.08) per 10 ml/min per 1.73 m^2^, respectively. Results were not altered by inclusion of ACE inhibitor use as a covariate or evaluation of systolic and diastolic blood pressures as continuous variables.

###### 

Associations of kidney disease with mortality among 691 CHS participants with diabetes

                                                                      Total mortality   CV mortality                                                                           
  ------------------------------------------------------------------- ----------------- -------------- ------------------- ------------------- ----- ----- ------------------- -------------------
  Cystatin C--estimated GFR                                                                                                                                                    
      ≥60 ml/min per 1.73 m^2^                                        217               6.0            1.00 (ref)          1.00 (ref)          94    2.6   1.00 (ref)          1.00 (ref)
      \<60 ml/min per 1.73 m^2^                                       161               12.2           1.81 (1.45--2.25)   1.73 (1.37--2.18)   75    5.7   2.00 (1.45--2.77)   1.71 (1.21--2.42)
      Per 10 ml/min per 1.73 m^2^ lower estimated GFR                                                  1.23 (1.15--1.30)   1.22 (1.14--1.30)               1.26 (1.15--1.38)   1.21 (1.10--1.33)
  MDRD-estimated GFR                                                                                                                                                           
      ≥60 ml/min per 1.73 m^2^                                        276               6.9            1.00 (ref)          1.00 (ref)          125   3.1   1.00 (ref)          1.00 (ref)
      \<60 ml/min per 1.73 m^2^                                       102               11.0           1.62 (1.28--2.04)   1.54 (1.21--1.97)   44    4.7   1.56 (1.10--2.22)   1.36 (0.94--1.96)
      Per 10 ml/min per 1.73 m^2^ lower estimated GFR                                                  1.13 (1.08--1.18)   1.12 (1.07--1.17)               1.14 (1.06--1.22)   1.11 (1.03--1.18)
  Loss of cystatin C--estimated GFR[§](#TF2-4){ref-type="table-fn"}                                                                                                            
      \<3 ml/min per 1.73 m^2^/year                                   271               7.0            1.00 (ref)          1.00 (ref)          113   2.9   1.00 (ref)          1.00 (ref)
      ≥3 ml/min per 1.73 m^2^/year                                    107               10.4           1.66 (1.30--2.11)   1.57 (1.22--2.01)   56    5.5   2.07 (1.46--2.92)   1.85 (1.29--2.65)
      Per ml/min per 1.73 m^2^/year decrease in estimated GFR                                          1.07 (1.02--1.12)   1.06 (1.01--1.10)               1.10 (1.04--1.17)   1.07 (1.01--1.13)
  Urine ACR                                                                                                                                                                    
      \<30 mg/g                                                       214               6.0            1.00 (ref)          1.00 (ref)          86    2.4   1.00 (ref)          1.00 (ref)
      ≥30 mg/g                                                        164               12.0           1.88 (1.52--2.32)   1.73 (1.39--2.17)   83    6.1   2.32 (1.70--3.18)   1.96 (1.40--2.73)
      Per doubling                                                                                     1.22 (1.15--1.30)   1.18 (1.10--1.26)               1.32 (1.20--1.45)   1.24 (1.12--1.37)

\*Per 100 person-years.

†Model 1 adjusted for age, sex, and race.

‡Model 2 adjusted for age, sex, race, diabetes duration, hypoglycemic medications, hypertension, BMI, smoking, total cholesterol, lipid-lowering medications, prevalent cardiovascular disease, and prevalent congestive heart failure.

§Loss of glomerular filtration rate estimated from serum cystatin C over the 7 years preceding ascertainment of mortality. ref, referent.

[Table 3](#T3){ref-type="table"} represents a comparison of the relative contributions to global mortality risk made by each of the four measures of kidney disease, after accounting for multiple covariates. eGFR~CYS~ was the strongest predictor of risk among these measures, leading to a high likelihood ratio and a c-index of 0.7645. Adding eGFR~CYS~ to a fully adjusted model that included eGFR~MDRD~ improved both the model likelihood ratio and the c-statistic, whereas adding eGFR~MDRD~ to a fully adjusted model that included eGFR~CYS~ resulted in no improvement in fit.

###### 

Contributions of kidney disease to prediction of total mortality among 691 CHS participants with diabetes

                                                                           Likelihood ratio test   c-statistic (95% CI)             
  ------------------------------------------------------------------------ ----------------------- ---------------------- --------- -----------------------------
  Base model[†](#TF3-2){ref-type="table-fn"}                               **175.24**                                               **0.7385** (0.7046--0.7783)
      + Cystatin C--estimated GFR                                          212.14                  36.90                  \<0.001   0.7654 (0.7319--0.8026)
      + MDRD-estimated GFR                                                 198.50                  23.26                  \<0.001   0.7550 (0.7221--0.7939)
      + Change in cystatin C--estimated GFR                                180.12                  4.88                   0.019     0.7421 (0.7082--0.7814)
      + Urine ACR                                                          189.82                  14.58                  0.009     0.7525 (0.7114--0.7844)
  Base model[†](#TF3-2){ref-type="table-fn"} + MDRD-estimated GFR          **198.50**                                               **0.7550** (0.7221--0.7939)
      + Cystatin C--estimated GFR                                          212.83                  14.33                  \<0.001   0.7674 (0.7319--0.8026)
  Base model[†](#TF3-2){ref-type="table-fn"} + cystatin C--estimated GFR   **212.14**                                               **0.7654** (0.7319--0.8026)
      + MDRD-estimated GFR                                                 212.83                  0.69                   0.916     0.7674 (0.7319--0.8026)
      + Change in cystatin C--estimated GFR                                212.24                  0.10                   0.834     0.7676 (0.7319--0.8026)
      + Urine ACR                                                          219.28                  7.14                   0.274     0.7746 (0.7336--0.8041)

\**P* value tests whether model with variable differs from corresponding base model in bold.

†Adjusted as per [Table 2](#T2){ref-type="table"}, model 2, without estimated GFR or urine ACR.

Change in cystatin C versus baseline cystatin C
-----------------------------------------------

Loss of eGFR~CYS~ before 1996--1997 was also associated with increased risk of mortality, with a strength of association somewhat less than that for a single 1996--1997 eGFR~CYS~ measurement ([Table 2](#T2){ref-type="table"}). When both eGFR~CYS~ and loss of GFR were included simultaneously in the fully adjusted model, eGFR~CYS~ but not loss of GFR was associated with increased risk of mortality with HRs of 1.22 (95% CI 1.14--1.31) per 10 ml/min per 1.73 m^2^ and 1.00 (0.95--1.04) per ml/min per 1.73 m^2^/year, respectively. Prediction models suggested that loss of GFR added substantially less to mortality prediction than a single eGFR~CYS~ measurement, and loss of GFR did not predict mortality when included in a model with eGFR~CYS~ ([Table 3](#T3){ref-type="table"}). Cystatin C concentrations were highly correlated within individuals over time, as evidenced by a regression dilution ratio of 0.74 (95% CI 0.70--0.79).

Cystatin C and albuminuria
--------------------------

Elevated urine ACR was a strong predictor of mortality, particularly cardiovascular mortality ([Table 2](#T2){ref-type="table"}). When both eGFR~CYS~ and urine ACR were included simultaneously in the fully adjusted model, each was independently associated with increased risk of mortality with HRs of 1.18 (95% CI 1.11--1.26) per 10 ml/min per 1.73 m^2^ and 1.11 (1.04--1.20) per doubling, respectively. Urine ACR added to prediction of mortality with or without simultaneous inclusion of eGFR~CYS~, as demonstrated by likelihood ratios and a change in the c-statistic ([Table 3](#T3){ref-type="table"}). Urine ACR and eGFR~CYS~ were additive in regard to mortality risk. Specifically, a reduction in cumulative survival among participants with low eGFR~CYS~ was nearly identical to that for participants with elevated urine ACR, and this reduction was approximately doubled among participants with both low eGFR~CYS~ and elevated urine ACR ([Fig. 1](#F1){ref-type="fig"}). Compared with participants with normal eGFR~CYS~ (≥60 ml/min per 1.73 m^2^) and normal urine ACR (\<30 mg/g), fully adjusted HRs for mortality were 1.69 (95% CI 1.26--2.27) for impaired eGFR~CYS~ (\<60 ml/min per 1.73 m^2^) and normal urine ACR, 1.67 (1.23--2.28) for normal low eGFR~CYS~ and elevated urine ACR (≥30 mg/g), and 2.54 (1.88--3.44) for both low eGFR~CYS~ and elevated urine ACR. There was no interaction on the multiplicative scale (interaction *P* = 0.634) or the additive scale (synergy index 1.14 \[95% CI 0.48--1.79\]).

![Cumulative survival by GFR estimated from serum cystatin C (milliliters per minute per 1.73 m^2^) and urine ACR (milligrams per gram) among 691 CHS participants with diabetes.](zdc0100978240001){#F1}

CONCLUSIONS
===========

Albuminuria and impaired GFR were independent, additive risk factors for mortality among older adults with diabetes. GFR estimated using serum cystatin C was more strongly associated with mortality than GFR estimated using serum creatinine. These findings support current recommendations to regularly assess both albuminuria and GFR in the clinical care of patients with diabetes ([@B4]) with a sharp focus on interventions to prevent or treat CVD in the presence of albuminuria, impaired GFR, or both and further consideration of cystatin C use in clinical care.

The additive prognostic utilities of albuminuria and impaired GFR are consistent with prior studies in populations without diabetes or with low diabetes prevalence ([@B8],[@B16][@B17][@B18][@B19]--[@B20]). Demonstration of this relationship in a diabetic population is particularly useful, because this population has a high cardiovascular risk and is well suited for regular health screening. Our results are similar and complementary to those from a Hong Kong cohort in which associations of albuminuria and estimated GFR with incident cardiovascular events were assessed ([@B3]). In contrast, an Italian study of type 2 diabetes observed albuminuria to be the primary renal risk factor for mortality, with estimated GFR being an independent risk factor only at levels \<30 ml/min per 1.73 m^2^ ([@B5]). Our results may differ from results for the Italian study owing to older participant age or to use of serum cystatin C to estimate GFR.

In our study, 53% of participants with impaired GFR (eGFR~CYS~ \<60 ml/min per 1.73 m^2^) had urine ACR \<30 mg/g. This proportion is higher than that observed in NHANES III, ([@B21]) possibly because of *1*) the added effects of diabetes and advanced age on GFR and *2*) more sensitive detection of impaired GFR using serum cystatin C. This large proportion of participants with impaired GFR but normal urine ACR is similar to that observed in the UK Prospective Diabetes Study ([@B22]), and, when combined with the independent and additive associations of each kidney disease measure with mortality, supports the general concept that albuminuria and impaired GFR are separate but overlapping, complementary manifestations of diabetic kidney disease. This concept has recently emerged as an alternative to an earlier paradigm describing albuminuria and impaired GFR as serial manifestations of diabetic kidney disease along a single, linear disease pathway ([@B23],[@B24]).

Thus, albuminuria and impaired GFR may reflect different pathways of kidney damage. Albuminuria may reflect widespread vascular damage and endothelial dysfunction, thus identifying susceptibility to disease in nonrenal vascular beds ([@B25]). Impaired GFR may reflect loss of nephrons and parenchymal fibrosis that leads to CVD through accumulation of uremic toxins, impaired volume and blood pressure regulation, and multiple metabolic abnormalities. Whether albuminuria and impaired GFR lead to CVD through distinct mechanisms, thus requiring distinct interventions, has not been established.

The association of cystatin C--estimated GFR with mortality was modestly stronger than that for GFR estimated from serum creatinine. This finding is consistent with prior studies using the full CHS population ([@B6],[@B7]). These studies demonstrated *1*) that cystatin C--estimated GFR was linearly associated with mortality risk, whereas MDRD-estimated GFR demonstrated a U-shaped association with mortality, and *2*) that elevated serum cystatin C was associated with mortality when MDRD-estimated GFR was in the "normal" range. It is possible that cystatin C estimates true GFR more precisely in the near-normal range or that cystatin C is less susceptible to confounding by body size among older adults. We evaluated only one formula estimating GFR from cystatin C, which was developed among individuals with impaired kidney function, and other cystatin C--based formulas may perform differently.

In our study, a change in cystatin C--estimated GFR within individuals over time was not associated with mortality more strongly than a single baseline cystatin C measurement. This result may be explained in part by the relatively high correlation of cystatin C concentration within individuals over time and suggests that single cystatin C measurements carry important prognostic information on their own, even without prior context. However, the value of longitudinal measurements may be increased when more measurements per individual are available.

Limitations of this study include the availability of only a single urine ACR measurement and lack of data assessing current glycemic control. Notably, however, we were able to account for diabetes duration and the use of hypoglycemic medications, which reflect cumulative exposure to hyperglycemia and disease severity and have been associated with mortality in CHS ([@B14]). In addition, our findings may not extrapolate to younger diabetic populations. Study strengths include the diverse, community-based diabetic population, multiple measurements of kidney disease, long-term follow-up for mortality and adjudicated CVD events, and large numbers of events to facilitate study of kidney disease interactions.
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